LY-2109761: Difference between revisions
CSV import |
No edit summary |
||
| (One intermediate revision by the same user not shown) | |||
| Line 20: | Line 20: | ||
{{stub}} | {{stub}} | ||
<gallery> | |||
File:LY-2109761 structure.png|LY-2109761 | |||
</gallery> | |||
Latest revision as of 00:23, 17 March 2025
LY-2109761 is a small molecule inhibitor that targets transforming growth factor beta receptor types I and II (TGFβRI/II). It has been studied for its potential use in the treatment of cancer, particularly in inhibiting the growth and spread of tumor cells.
Mechanism of Action[edit]
LY-2109761 works by inhibiting the kinase activity of TGFβRI/II. This prevents the phosphorylation of SMAD proteins, which are crucial for the transmission of TGFβ signals from the cell surface to the nucleus. By blocking this signaling pathway, LY-2109761 can inhibit the growth and spread of tumor cells.
Clinical Trials[edit]
Several clinical trials have been conducted to evaluate the safety and efficacy of LY-2109761 in the treatment of various types of cancer. These trials have shown promising results, with LY-2109761 demonstrating significant anti-tumor activity in preclinical models of pancreatic cancer and hepatocellular carcinoma.
Potential Side Effects[edit]
As with any drug, LY-2109761 may cause side effects. These can include nausea, vomiting, diarrhea, and fatigue. However, these side effects are generally mild and manageable with appropriate medical intervention.
Future Research[edit]
Further research is needed to fully understand the potential benefits and risks of LY-2109761. This includes additional clinical trials to evaluate its efficacy in other types of cancer, as well as studies to explore its mechanism of action in more detail.
